Cargando…
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-li...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363595/ https://www.ncbi.nlm.nih.gov/pubmed/11027433 http://dx.doi.org/10.1054/bjoc.2000.1415 |
_version_ | 1782153743961161728 |
---|---|
author | Walter, W Lingnau, K Schmitt, E Loos, M Maeurer, M J |
author_facet | Walter, W Lingnau, K Schmitt, E Loos, M Maeurer, M J |
author_sort | Walter, W |
collection | PubMed |
description | Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the β-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1β-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) α-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-γ) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Mαβ1 and Mαβ2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-γ-treatment; and lack of constitutive and IFN-γ-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2363595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23635952009-09-10 MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Walter, W Lingnau, K Schmitt, E Loos, M Maeurer, M J Br J Cancer Regular Article Qualitative differences in the MHC class II antigen processing and presentation pathway may be instrumental in shaping the CD4+ T cell response directed against tumour cells. Efficient loading of many MHC class II alleles with peptides requires the assistance of H2-M, a heterodimeric MHC class II-like molecule. In contrast to the HLA-DM region in humans, the β-chain locus is duplicated in mouse, with the H2-Mb1 (Mb1β-chain distal to H2-Mb2 (Mb2) and the H2-Ma (Ma) α-chain gene). Here, we show that murine MHC class II and H2-M genes are coordinately regulated in murine tumour cell lines by T helper cell 1 (IFN-γ) and T helper cell 2 (IL-4 or IL-10) cytokines in the presence of the MHC class II-specific transactivator CIITA as determined by mRNA expression and Western blot analysis. Furthermore, Mαβ1 and Mαβ2 heterodimers are differentially expressed in murine tumour cell lines of different histology. Both H2-M isoforms promote equally processing and presentation of native protein antigens to H2-A(d)- and H2-E(d)-restricted CD4+ T cells. Murine tumour cell lines could be divided into three groups: constitutive MHC class II and CIITA expression; inducible MHC class II and CIITA expression upon IFN-γ-treatment; and lack of constitutive and IFN-γ-inducible MHC class II and CIITA expression. These differences may impact on CD4+ T cell recognition of cancer cells in murine tumour models. © 2000 Cancer Research Campaign Nature Publishing Group 2000-11 /pmc/articles/PMC2363595/ /pubmed/11027433 http://dx.doi.org/10.1054/bjoc.2000.1415 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Walter, W Lingnau, K Schmitt, E Loos, M Maeurer, M J MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title | MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title_full | MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title_fullStr | MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title_full_unstemmed | MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title_short | MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
title_sort | mhc class ii antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363595/ https://www.ncbi.nlm.nih.gov/pubmed/11027433 http://dx.doi.org/10.1054/bjoc.2000.1415 |
work_keys_str_mv | AT walterw mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance AT lingnauk mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance AT schmitte mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance AT loosm mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance AT maeurermj mhcclassiiantigenpresentationpathwayinmurinetumourstumourevasionfromimmunosurveillance |